Aimovig
(Erenumab)ApprovedMonoclonal antibody
AmgenErenumab is used to prevent migraines by blocking a protein in the brain called CGRP that is involved in migraine pain. It is given as a monthly injection to reduce how often migraines occur.[2] Aimovig is currently approved and in use across 18 indications[4].[1]
Aimovig is one of 342 monoclonal antibody programs targeting Hyperprolactinemia. It is currently in Approved.
18
Indications
56
Total Trials
7
Active Trials
341
Competitors
1
FDA Application
NDA/BLA/ANDA regulatory filings
Pipeline
Status by Indication[4][1]
Indication
Showing 10 of 17 indications
Competition
Competitive Landscape
1931 competitors in COVID-19
#DrugCompanyPhaseTrials
1Aimovig
AmgenApproved
Rayaldee
OOrganon and Co
Preclinical
Statins
SanofiPreclinical
Aprotinin
BayerPreclinical
Olokizumab
UCBPreclinical
Antithrombin-III
OctapharmaPreclinical
DAS181
AAnsun Biopharma, Inc.
Preclinical
Opaganib
RRedHill Biopharma Limited
Preclinical
Covid Infection
KKing's College London
Preclinical
Saliva Collection
DDirection Centrale du Service de Santé des Armées
Preclinical
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Timeline
Expected Milestones
Clinical
Trials by Indication[1]
Migraine33 trials
Show 30 more trials
Neurophysiological, Biomolecular and Psychological Aspects of Erenumab Treatment in Chronic Migraine
Unknown status·IIRCCS National Neurological Institute "C. Mondino" Foundation··NCT04361721·40 enrolled
Headache3 trials
Treatment3 trials
Treatment of Acute PTH With a CGRP Receptor mAb in Military Service Members and Civilians With mTBI
Recruiting·HHenry M. Jackson Foundation for the Advancement of Military Medicine·Phase 2·NCT05049057·404 enrolled
Interaction2 trials
14 more indications
Facial Pain1 trial
Erenumab for Idiosyncratic Facial Pain
Completed·—·Phase 4·NCT04249427·29 enrolled
Temporomandibular Disorders1 trial
COVID-191 trial
Prevention1 trial
Cluster headache1 trial
Efficacy of Erenumab in Chronic Cluster Headache
Completed·—·Phase 2·NCT04970355·101 enrolled
Trigeminal Neuralgia1 trial
Blood Pressure1 trial
Regulatory
FDA Approval Timeline[5]
May 17, 2018
AIMOVIG
BLA BLA761077
Sources
References
- [1]
- [2]MedlinePlus Drug Information — Aimovig drug information. U.S. National Library of Medicine, National Institutes of Health.
- [3]
- [4]Open Targets Platform — Drug–disease associations for Erenumab. EMBL-EBI & Wellcome Sanger Institute.
- [5]
- [6]
- [7]